), a leader in non-invasive monitoring technology for patient
care, recorded first quarter 2013 earnings per share of 28 cents
thereby matching the Zacks Consensus Estimate. Reported profit
rose 4.1% year over year to $16.4 million (or 28 cents per share)
in the first quarter.
Revenues in the quarter increased 14% year over year to $135.9
million, beating the Zacks Consensus Estimate of $134
Product revenues were up 15% to $128.6 million in the reported
quarter. Masimo's global end-user business (84% of product
revenue) improved 13% year over year, while revenues from
Original Equipment Manufacturer or OEM (16% of product revenue)
were up 26%. Sales of rainbow products increased 24% year over
year to $10.5 million.
During the quarter, Masimo shipped about 39,500 Masimo SET
pulse oximetry and Masimo rainbow SET pulse co-oximetry units,
excluding hand-held sets, up 19% year over year. The company's
worldwide installed base increased 11% year over year to about
1,117,000 units at the end of the first quarter.
Gross margin stood at 65.9% in the quarter, lower than 66.5% a
year ago. Operating margin declined to 17% from 18.7% a year
Masimo ended the quarter with cash and cash equivalents of
$81.6 million, up 14% year over year.
Masimo is a market leader in the pulse oximetry monitoring
equipment industry. The company's prospects are encouraging,
given the sizeable global market opportunity, adoption of pulse
oximetry in non-critical areas of the hospital and growing
barriers to entry due to additional non-invasive parameters.
While Masimo's patented SET offering remains its mainstay, the
rainbow measurements represent another growth driver. However,
the company's reliance on third-party providers like OEMs for a
part of its business and customer concentration raises concern.
Additionally, we remain concerned about Masimo's reliance on
group purchasing organizations for the sale of its pulse oximetry
products to hospitals in the domestic market.
We also note
) effort to expand its oximetry and monitoring products
portfolio. In late 2012, the company won U.S. Food and Drug
Administration (FDA) 510(k) approval as well as European Economic
Area (EEA) CE Mark clearance for its Nellcor Bedside Respiratory
Patient Monitoring system.
The stock carries a Zacks Rank #3 (Hold). We are more positive
) both of which carry a Zacks Rank #2 (Buy) and are expected to
ABIOMED INC (ABMD): Free Stock Analysis
ACCURAY INC (ARAY): Free Stock Analysis
COVIDIEN PLC (COV): Free Stock Analysis
MASCO (MAS): Free Stock Analysis Report
To read this article on Zacks.com click here.